The Clinical and Regulatory Milestone of Zongertinib in First-Line NSCLC
Episode Summary
FDA grants accelerated first-line approval to zongertinib, a selective oral HER2 TKI, redefining treatment for HER2-mutant metastatic NSCLC with high response rates and precision-first strategy.